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We reported that knockdown of PPP2R5C by siRNA led to proliferation inhibition and apoptosis induction in K562
cells. In this study, we further characterized the gene expression profiles after PPP2R5C suppression by microarray
analysis. Genes which participate in the MAPK, PI3K/AKT, and JAK/STAT pathways, were mainly altered in the K562
cells. We propose that the mechanism for proliferation inhibition and increased apoptosis of K562 cells following
PPP2R5C suppression may be related to the alteration of expression profiles of BRAF, AKT2, AKT3, NFKB2 and STAT3
genes.
Keywords: PPP2R5C, CML, BCR-ABL, Gene expression profileFindings
Overexpression of PPP2R5C is associated with the ma-
lignant transformation of several kinds of leukemia [1].
Recently we characterized the effects of downregulating
PPP2R5C on the proliferation and apoptosis of K562
and Jurkat cells using different siRNAs which were tar-
geting PPP2R5C. Significant proliferation inhibition was
confirmed both in K562 and Jurkat cells, whereas apop-
tosis induction could only be observed in K562 and
K562R cells [2,3].
To further investigate the gene expression profile,
PPP2R5C-siRNA991-treated K562 cells were collected at
48 h post transfection when PPP2R5C mRNA was most
suppressed [2]. Gene expression profiles were determined
and analyzed by Affymetrix microarrays as reported (See
Additional file 1 for methods and materials) [3,4]. Overall,* Correspondence: yangqiuli@hotmail.com
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unless otherwise stated.2,586 genes were upregulated and 2,601 genes were down-
regulated at least two-fold, when PPP2R5C-siRNA991 and
SC-treated expression data were compared. We also found
both the Bcr and Abl genes were downregulated (fold
change: −1.23 and −1.53, respectively), suggesting that
PPP2R5C is closely related to the BCR-ABL-mediated
pathway. Besides that, there were changes in genes in-
volved in different signaling pathways closely related to cell
proliferation and apoptosis (Table 1, Figure 1A and B).
Aberrant BCR-ABL tyrosine kinase activity plays a cru-
cial role in the pathogenesis of CML [5,6]. Moreover, ab-
normal interactions between the BCR-ABL oncoprotein
and other molecules lead to the disruption of the major
cellular processes, including the MAPK, JAK/STAT and
PI3K/AKT signaling pathway, which can result in the dys-
regulation of proliferation and apoptosis [7].
In the MAPK signaling pathway, 67 genes were differen-
tially expressed including 20 upregulated and 47 downreg-
ulated genes. The significantly downregulated genes
including BRAF, MAP2K2, ELK1, NFKB2, FOS, and
JUN. Downregulated BRAF might decrease the expressions is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,






BRAF NM_004333 −2.24 v-raf murine sarcoma viral oncogene homolog B1 MAPK signaling pathway
MAP2K2 NM_030662 −2.39 mitogen-activated protein kinase kinase 2 MAPK signaling pathway
ELK1 NM_001114123 −2.65 ELK1, member of ETS oncogene family MAPK signaling pathway
FOS NM_005252 −3.12 FBJ murine osteosarcoma viral oncogene homolog MAPK signaling pathway





−2.81 nuclear factor of kappa light polypeptide gene enhancer
in B-cells 2 (p49/p100)
AKT2 NM_001626 −2.72 V-akt murine thymoma viral oncogene homolog 2 MAPK signaling pathway/AKT signaling
pathway
AKT3 NM_005465 −12.47 v-akt murine thymoma viral oncogene homolog 3 (protein
kinase B, gamma)
MAPK signaling pathway/AKT signaling
pathway
CRKL NM_005207 −2.14 v-crk sarcoma virus CT10 oncogene homolog (avian)-like MAPK signaling pathway/AKT signaling
pathway




−5.08 signal transducer and activator of transcription 3
(acute-phase response factor)
MDM2 NM_002392 2.26 Mdm2 p53 binding protein homolog AKT Signaling Pathway/p53Signaling
Pathway
ATM NM_000051 −2.30 ataxia telangiectasia mutated p53Signaling Pathway
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ELK1, NFKB2, FOS and JUN (Figure 1C) [8]. As a conse-
quence, the major effects of the proliferation inhibition in
PPP2R5C-siRNA991-treated K562 cells might be via the
BRAF inhibition.
There were alterations involved in the PI3K/AKT sig-
naling pathway including 6 upregulated and 6 down-
regulated genes (Figure 1D). PPP2R5C suppression
predominantly resulted in MDM2 upregulation and
downregulation of CRKL, AKT2, AKT3, and NFKB2.
PI3K activates AKT kinases and causes the phosphor-
ylation of downstream factors that regulate the AKT-
mediated cellular apoptotic machinery [8,9], while
downregulation of CRKL weakens BCR-ABL binding to
PI3K, leading to reduced AKT phosphorylation. More-
over, a reduction in NFKB2 might be directly linked to
the induction of apoptosis [10], and MDM2, a negative
regulator of p53, might indirectly affect apoptosis [11].
Therefore, it is thought that AKT2, AKT3 and NFKB2
might be involved in apoptosis induction in K562 cells
after PPP2R5C inhibition.
In the JAK/STAT signaling pathway, 28 genes were
differentially expressed, including 16 upregulated and
12 downregulated genes (Figure 1E). The downregu-
lated genes IL6ST and STAT3 may play important roles
in cell proliferation through inhibition of the IL-6/
JAK/STAT3 pathway, and STAT3, which is a signal
transducer, plays a key role in cell survival in humanhematopoietic malignancies [12]. Thus, PPP2R5C sup-
pression might have effect on the JAK/STAT pathway
through STAT3 downregulation, leading to prolifera-
tion inhibition in K562 cells.
Because the mediation of cell proliferation, differenti-
ation, and transformation functions of PPP2R5C is
based on its induction of p53 dephosphorylation at
various residues [13,14], a dominant alteration in p53
pathway was found for ATM, which had 2.3-fold down-
regulation, and MDM2, which was upregulated 2.26-
fold. These results are similar to our previous finding
in Jurkat cells in which we showed that proliferation
was suppressed by PPP2R5C-siRNA. It is thought that
ATM downregulation and MDM2 upregulation might
lead to a decreased transcriptional activation level for
p53, suggesting that the PPP2R5C-mediated p53 func-
tion might use the same signaling pathway in different
leukemia cells.
In conclusion, we characterized altered expression
profile of genes related to the BCR-ABL signaling
pathway in PPP2R5C-siRNA-treated K562 cells. The
mechanism of PPP2R5C-suppression-mediated inhi-
bition of proliferation and increased apoptosis in K562
cells may be related to the MAPK, PI3K/AKT, JAK/
STAT pathways through BRAF, AKT2, AKT3, NFKB2
and STAT3 downregulation. However, further valid-
ation of the altered genes and related proteins is
needed.
Figure 1 Microarray analysis for gene expression profiles of K562 cells after transfection with PPP2R5C-siRNA991. (A) Scatter plots comparing
the gene expression profiles of siRNA991 and scrambled control (SC) transfected cells. The yellow dots represent genes undetected in both
samples, blue dots represent genes present in both samples, red dots represent upregulated genes, and green dots represent downregulated
genes. (B) The Affymetrix data were clustered, and the red and green colors represent the expression levels increased or decreased, respectively,
with respect to the average expression across all samples. (C) PI3K/AKT signaling pathway genes differentially expressed in K562 cells after
PPP2R5C suppression. (D) JAK/STAT signaling pathways genes differentially expressed in K562 cells after PPP2R5C suppression. (E) Schematic
model of the BCR-ABL-mediated BRAF-MEK-FOS-JUN signaling pathway due to PPP2R5C suppression in K562 cells (modified from reference [8]).
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